Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trastuzumab biosimilar - Merck & Co./Samsung Bioepis

Next Previous
Drug Profile

Trastuzumab biosimilar - Merck & Co./Samsung Bioepis

Alternative Names: AMT-901; Ontruzant; Samfenet; SB3; Trastuzumab-biosimilar-Samsung Bioepis; trastuzumab-dttb

Latest Information Update: 23 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Samsung Bioepis
  • Developer Merck & Co; Organon; Samsung Bioepis
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Adenocarcinoma; Gastric cancer; HER2 positive breast cancer

Most Recent Events

  • 14 Nov 2022 Launched for Gastric cancer (Metastatic disease) in Canada, Canada (IV)
  • 14 Nov 2022 Launched for HER2-positive-breast-cancer (Early-stage disease) in Canada, Canada (IV)
  • 14 Nov 2022 Launched for HER2-positive-breast-cancer (Metastatic disease) in Canada, Canada (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top